“We’re going from 300,000 doses of Pfizer a week to 600,000 doses, and we’ll be making those doses available as quickly as possible.”
“But we have had issues with the AstraZeneca vaccine, as you know, based on the blood clots that have been caused in some recipients. So, those have been issues beyond our control and the AstraZeneca vaccine has been the one that we have been making under licence by CSL here in Australia.
“But the fact is we’re focused on the most vulnerable cohorts … and the over-50s — we’ve already seen more than 50 per cent of people receive their first dose. In the over-60s, around 60 per cent have received their first dose, and for the over-70s, nearly 70 per cent have received their first dose.
“I think we’re entering a new phase of this pandemic, with the more contagious Delta strain.”